Highbury Group Research
Investment Thesis
Highbury Group is an early-stage venture capital firm founded in 2013 by Dr. Ling Wong, a serial entrepreneur, scientist, and inventor. The firm's thesis centers on partnering with mission-oriented founders working on transformational ideas that can have a positive, lasting impact on society. The firm is particularly focused on companies that use science and technology to improve human health and better humanity in lasting ways.
Dr. Wong's background as the inventor of the world's first inhaled TB vaccine and her experience as both an operator and investor inform the firm's approach. She brings a multidisciplinary perspective that emphasizes deep domain expertise and an understanding of complex scientific and technical challenges. Highbury Group operates as a trusted partner to entrepreneurs, providing not just capital but strategic guidance rooted in real-world operational experience.
Sector Focus
Highbury Group invests across several complementary sectors:
Healthcare & Healthcare Technology:
- Digital health and telehealth platforms
- Healthcare software and health IT solutions
- Insurance and managed care innovation
- Preventive care and wellness
- Medical devices and diagnostics
Biotechnology & Life Sciences:
- Early-stage biotech and therapeutics
- Biomedical innovations
- Synthetic biology and gene therapy
- Life sciences tools and enabling technologies
Enterprise Software & Consumer Technology:
- B2B SaaS solutions
- Consumer health and wellness apps
- Data analytics and business intelligence
- Payments and financial technology
- Productivity and workflow tools
Investment Stage and Check Size
Highbury Group is an early-stage investor with a focus on:
Stage Focus:
- Pre-Seed: $100K-$500K for teams with innovative ideas and early validation
- Seed: $500K-$1.5M for companies with product-market fit signals
- Selective Series A follow-ons in existing portfolio companies
Check Size: Typical range $100K-$1M, with capacity to lead small seed rounds
The firm operates as a solo GP structure, allowing for flexible, responsive investments and deep engagement with portfolio companies.
Lead Tendency
Highbury Group demonstrates a balanced investment approach. Dr. Wong often takes board seats or advisory roles in investments, indicating active engagement. The firm both leads rounds (particularly in seed stage) and co-invests with strong syndicate partners. The emphasis on being a "true partner and champion" suggests a preference for meaningful ownership stakes and hands-on involvement rather than passive follow-on investments.
Recent Activity
Highbury Group has been actively deploying capital across healthcare and technology investments:
Notable Recent Investments:
- December 2023: Series E in Devoted Health ($175M round) - Medicare Advantage platform
- 2024-2025: Active in seed and series A investments across healthcare and enterprise software
- Ongoing portfolio engagement and follow-on investments
The firm maintains an actively deploying status with continued investment activity as of early 2026.
Portfolio Highlights
Notable Unicorn/Billion-Dollar Companies:
- Devoted Health - Medicare Advantage platform, raised $2.3B+ across rounds
- Orca Bio - Biotech company (unicorn)
- Collective Health - Healthcare benefits platform (unicorn)
- Color - Genetic testing platform (unicorn)
- Apeel - Food preservation technology (unicorn)
- Shape - Healthcare technology (unicorn)
- Stripe - Payments infrastructure ($95B+ valuation)
- Notion - Productivity software (unicorn)
- Guardant Health - Cancer diagnostics (NASDAQ: GH)
Notable Exits:
- Anacor Pharmaceuticals (acquired by Pfizer for $5.2B)
- Visterra (acquired for $430M)
- Slack (acquired by Salesforce for $27.7B)
- Singular Genomics (NASDAQ: OMIC)
- Science.io (acquired by Veradigm)
- Genocea Biosciences (NASDAQ: GNCA)
Portfolio Size: 25+ active investments representing strong performance across healthcare and technology sectors.
Team
Dr. Ling Wong - Founder and General Partner
- Background: PhD from Harvard University, BSc in Chemical Engineering and Biology from MIT
- Experience: Inventor of the world's first inhaled TB vaccine, former researcher at MIT Langer Lab
- Career: Serial entrepreneur and investor with 15+ years of experience
- Roles: Currently Senior Advisor to Lightspeed Venture Partners in addition to managing Highbury Group
- Also founder of Sea Lane Ventures
The firm operates with a small, specialized team that allows for deep engagement and personalized support to portfolio companies.
Investment Decision Process
As a solo GP fund structure, Highbury Group operates with Dr. Wong as the primary decision-maker. The firm's approach emphasizes:
- Deep technical and scientific diligence
- Assessment of founder quality and mission alignment
- Understanding of market dynamics and competitive positioning
- Operational support and active involvement post-investment
Founder Preferences
Highbury Group seeks founders who:
- Have clear mission-oriented vision with societal impact focus
- Bring deep technical expertise and domain knowledge
- Demonstrate strong execution capability
- Come from science, engineering, or technical backgrounds
- Are committed to building transformational companies
- Show understanding of complex problems they're solving
The firm has particular strength in backing founders from academic and research backgrounds given Dr. Wong's own trajectory.
Geographic Focus
Primarily United States-focused with particular strength in:
- Seattle/Pacific Northwest region (headquarters location)
- San Francisco Bay Area (tech and healthcare innovation hubs)
- New York/Boston (healthcare and biotech clusters)
- Select investments nationally in strong teams and markets
Co-Investment Patterns
Highbury Group frequently co-invests with:
- Lightspeed Venture Partners
- Other mission-driven early-stage investors
- Strategic corporate investors in healthcare
- Academic and research-based investor networks
Fund Status
The firm operates with approximately $300M in assets under management, maintains an actively deploying status, and continues to make new investments as of early 2026. The solo GP structure allows for responsiveness to exceptional investment opportunities.
What Makes Highbury Different
Highbury Group stands out through:
- Founder's Unique Background: Dr. Wong's inventor, scientist, and entrepreneur pedigree brings rare expertise
- Mission-Driven Approach: Focus on companies with societal impact, not just financial returns
- Active Partnership: Emphasis on hands-on engagement and operational support
- Cross-Sector Perspective: Experience across biotech, healthcare, enterprise software, and consumer technology
- Track Record: Portfolio includes multiple unicorns and successful exits exceeding $5B+ in value
- Solo GP Model: Flexibility and personalized attention to founders and investments